This study is for adults aged 18 or older who are obese and have a liver disease called MASH (non-alcoholic steatohepatitis) with moderate or advanced liver fibrosis. People with other liver diseases or those with high alcohol intake cannot join. The study examines if a medicine called survodutide can help improve liver function. Participants are split into two groups randomly: one gets survodutide, and the other gets a placebo (a harmless pill with no medical effect). The study lasts up to 7 years, and participants visit the study site or have video calls regularly for health checks.

• The study duration is up to 7 years with regular visits or calls.
• Participants must inject medication weekly and follow a stable diet and exercise plan.
• Doctors monitor health and side effects, with some liver tests and questionnaires about symptoms and life quality.